Discovery & Protein Engineering
- Molecular and structural biology
- Protein and antibody engineering
- In silico manufacturing assessment
- Antibody discovery by phage display
- Antibody‑drug conjugates & bioconjugation
The University of Queensland
National Biologics Facility
Australia's national facility for recombinant protein and biologics, from research-grade supply through to Phase I clinical-grade manufacture.
Discover Our CapabilitiesLatest News
NBF News
From clinical trials to landmark partnerships, stay up to date with the breakthroughs and milestones emerging from Australia's leading biologics facility.
View All News
Announcement
PEF and NBF Unite Under One Banner
What We Do
From Gene to Clinical Drug Substance
Our integrated pipeline takes targets from gene synthesis and molecular engineering, through multi-host expression screening and scale-up, to Phase I clinical-grade drug substance, within a single facility, single quality system, single team.
01Discover
02Develop
Multi-Host & Stable Expression
- Mammalian cell line development
- High throughput clone selection
- Mammalian, microbial & insect systems
- Research grade manufacturing
Process Development & Scale Up
- Single-use systems
- Formulation screening
- Industry-relevant purification strategies
- Bioanalytics & characterisation
- Assay method development
03Translate
Phase I-Enabling Manufacturing
- Process scale up to 50 L
- QC/QA release of drug substance
- QC method qualification
- Stability monitoring
- Large scale PC2, ISO 9001
Where NBF Fits
From discovery to first-in-human
A biologic takes a decade or more to reach patients. NBF covers the first half of that journey, from the earliest research-grade protein through to the clinical-grade drug substance dosed in a Phase I trial.
NBF supports these stages
Programme
Discovery
Preclinical
Phase I
Phase II
Phase III
Oncology
Programme 1
Programme 2
Programme 3
Immunology
Programme 4
Programme 5
Vaccines
Programme 6
Programme 7
Cardiac
Programme 8
Programme 9
Supported by NBF
Sponsor and partners
Illustrative only. Example programmes across therapeutic areas, not NBF's client portfolio.
Programmes leave NBF with the research cell bank, bioprocess and analytical package that can enable seamless transition to later-phase development and larger-scale manufacture.
Who We Serve
Recombinant protein for research, industry and the clinic
Whether you need a single difficult target expressed for a research project or clinical-grade drug substance for first-in-human trials, NBF delivers recombinant protein at the scale and quality your programme requires, with no obligation to progress to clinical development.
Research & discovery proteins
Research-grade and reagent proteins, antigens for immunisation, and structural-biology and assay targets, from milligram to gram scale across four expression hosts.
Expression systems →
Diagnostic & industrial proteins
Diagnostic and biomarker proteins, recombinant enzymes and reference materials for industry and government, produced to consistent, quality-assured specifications.
Biologic modalities →
Clinical-grade biomanufacturing
Phase I clinical-grade drug substance for first-in-human trials, with master cell banking and release testing under an ISO 9001 quality management system.
Phase I manufacturing →Our People
A World-Class Team of Scientists & Engineers
Our multidisciplinary team brings decades of combined expertise across protein engineering, multi-host expression, bioprocess scale-up, analytics, project management, and ISO 9001 quality management, translating Australian discoveries from gene to clinical drug substance.
Meet the Team
Modalities Supported
One facility for every biologic modality
From monoclonal antibodies and antibody-drug conjugates to radioligand therapeutics, recombinant vaccines and therapeutic enzymes, NBF's platform supports the full spectrum of biologic modality classes through a single quality system.
Monoclonal antibodies (mAbs)
Bispecifics
Antibody fragments & nanobodies
Antibody-drug conjugates (ADCs)
Radioligand & radiopharmaceutical precursors
Recombinant vaccines
Fc-fusion proteins
Therapeutic enzymes
Diagnostic & biomarker proteins
Explore biologic modalities in detail
